Prediction of Unbound Vancomycin Levels in Intensive Care Unit and Nonintensive Care Unit Patients: Total Bilirubin May Play an Important Role

Xiao Li1,*, Wen Xu1,*, Ran Li2, Qie Guo1, Xiangpeng Li1, Jialin Sun1, Shuhong Sun1, Jing Li1

1Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266003, People’s Republic of China; 2Department of Infectious Diseases, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 266003, People’s Republic of China

*These authors contributed equally to this work

Background: The mean unbound vancomycin fraction and whether the unbound vancomycin level could be predicted from the total vancomycin level are still controversial, especially for patients in different groups, such as intensive care unit (ICU) versus non-ICU patients. Other relevant potential patient characteristics that may predict unbound vancomycin levels have yet to be clearly determined.

Methods: We enrolled a relatively large study population and included widely comprehensive potential covariates to evaluate the unbound vancomycin fractions in a cohort of ICU (n=117 samples) and non-ICU patients (n=73 samples) by using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.

Results: The mean unbound vancomycin fraction was 45.80% ± 18.69% (median, 46.01%; range: 2.13–99.45%) in the samples from the total population. No significant differences in the unbound vancomycin fraction were found between the ICU patients and the non-ICU patients (P=0.359). A significant correlation was established between the unbound and total vancomycin levels. The unbound vancomycin level can be predicted with the following equations: unbound vancomycin level=0.395×total vancomycin level+0.019×total bilirubin level+0.468 (R²=0.771) for the ICU patients and unbound vancomycin level=0.526×total vancomycin level-0.527 (R²=0.749) for the non-ICU patients. Overall, the observed-versus-predicted plots were acceptable.

Conclusion: A significant correlation between the total and unbound vancomycin levels was found, and measurement of the unbound vancomycin level seems to have no added value over measurement of the total vancomycin level. The study developed parsimonious equations for predicting the unbound vancomycin level and provides a reference for clinicians to predict the unbound vancomycin level in adult populations.

Keywords: unbound vancomycin fraction, unbound vancomycin level, patient characteristics, predictors

Background
Vancomycin, an important antibacterial agent, has been recommended as a first-line treatment for gram-positive infections, especially methicillin-resistant *Staphylococcus aureus*.1,2 It is well known that for vancomycin, a ratio of the area under the curve (AUC) concentration-time profile to the minimum inhibitory concentration (MIC) (AUC/MIC) of 400 or more can increase the likelihood of clinical cure and decrease the likelihood of toxicity.3,4 In recent guidelines, serum trough concentrations of 15 to
In the clinic, only the total vancomycin level is routinely measured.\textsuperscript{4} Moreover, dosage adjustments depend on a total drug target, even though it is known that for most antibiotics, including vancomycin, only the unbound fraction of drug is critical for antimicrobial activity.\textsuperscript{7–9} As a rule of thumb, a protein binding proportion of approximately 50\% is assumed.\textsuperscript{4,10,11} Some original studies concluded that the mean values of the unbound vancomycin fraction were 41.9\% ± 14.1\%\textsuperscript{12} and 0.54 ± 0.08\textsuperscript{13} and that the mean values of the bound vancomycin fraction were 41.5\% ± 8.6\%\textsuperscript{14} and 54.6\% ± 9.5\%,\textsuperscript{3} apparently justifying this rule of thumb. However, we found that the percentage protein binding of vancomycin reported in the literature ranges from nearly 0\% to almost 100\%,\textsuperscript{15–21} with great controversy. This controversy might be due to the differences in different patient groups, such as patients with hypoalbuminemia, burns, myeloma, and obesity, where serum protein concentrations had high variability in these groups.\textsuperscript{11,22–24} Notably, catabolism, systemic inflammation and multiple organ dysfunction may lead to plasma protein binding changes in ICU patients.\textsuperscript{25,26} Some published literature indicates that plasma protein binding changes of drugs are common in intensive care unit (ICU) patients,\textsuperscript{26,27} but this needs to be verified for the percentage protein binding of vancomycin.

In addition, some studies have concluded that the unbound vancomycin level could be predicted from the total vancomycin level.\textsuperscript{11,14,19–21} Contradictory results have also been reported in which the unbound vancomycin level could not be predicted from the total vancomycin level.\textsuperscript{18,25} Therefore, the mean value of the unbound fraction of vancomycin and whether the unbound vancomycin level could be predicted from the total vancomycin level remain controversial, especially for patients in different groups, such as ICU patients and non-ICU patients. In addition, other relevant potential patient characteristics, such as age, body mass index (BMI), creatinine level, cystatin C level, prealbumin level, total protein level, globulin level, albumin level, total bilirubin level, direct bilirubin level, and history of diabetes mellitus, heart failure, dialysis and hepatic dysfunction, that may account for alterations in the unbound vancomycin level have yet to be clearly determined.

Here, to address the aforementioned issues, we performed a study to evaluate the unbound vancomycin fractions in a large cohort of ICU and non-ICU patients by using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method and to examine the extent to which unbound and total vancomycin levels are correlated. In addition, this study also evaluated variables extracted from patient characteristics that may account for alterations in unbound vancomycin levels.

**Patients and Methods**

**Patients**

We conducted a retrospective, noninterventional study with archived samples from patients aged 18 years and older who received vancomycin for suspected or proven gram-positive infections and required routine total vancomycin therapeutic drug monitoring (TDM) between April 2018 and December 2019. Samples (n=71) from patients (n=57) were excluded from the following analysis because the archived plasma samples were insufficient. Samples (n=190) from patients (n=152) treated by intermittent infusion of vancomycin were analyzed. This study was approved by the Institute Medical Ethics Committee of the Affiliated Hospital of Qingdao University and was conducted in accordance with the ethical principles of the Declaration of Helsinki. As the study was performed with archived samples, the requirement for informed consent was waived by the Institute Medical Ethics Committee, but patient confidentiality was protected.

**Data Collection**

Patient data were collected by a review of the medical records. The baseline data collected were age, sex, BMI and location (ICU versus non-ICU). The treatment details consisted of drugs with high plasma protein binding (PPB) (>70\%) coadministered on the day of sampling, such as phenytoin, valproic acid, vitamin K antagonists, aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs).\textsuperscript{19} Biochemical data collected from the laboratory information system included total protein, prealbumin, albumin, globulin, total bilirubin, direct bilirubin, creatinine and cystatin C levels. These reported laboratory data were obtained on the day of sample collection for routine total vancomycin measurement. If a laboratory value was not measured on the day of sample collection, the closest value within 3 days of sample collection was chosen when available.

**Vancomycin Determination**

Archived plasma samples sent to the clinical pharmacy laboratory of the Affiliated Hospital of Qingdao
University for total vancomycin measurements were collected from the laboratory sample storage system (2°C to 8°C) at the end of the measurement day. Samples were centrifuged at 2000×g (37°C) for 5 min. One part was frozen (−20°C) for measurement of total vancomycin by LC-MS/MS, and another part was processed directly to obtain the unbound vancomycin fraction.

The part of each sample used to obtain the unbound vancomycin fraction was centrifuged with a Centrifree Centrifugal Filter Device (molecular weight cutoff, 30,000; Millipore, Billerica, MA). Briefly, 600 μL of plasma was incubated in the capped Centrifree Centrifugal Filter Device and centrifuged at 2000×g (37°C) for 30 min. The unbound vancomycin samples were ultrafiltered and stored at −20°C until analysis.

Unbound and total vancomycin levels were measured by LC-MS/MS. Triazolam was chosen as the internal standard (IS). For total vancomycin, 25 μL of blank plasma sample was added to each 25 μL of thawed sample and mixed. Fifty microliters of the mixture was extracted with 150 μL of methanol (containing 0.1 mg/L IS) after appropriate dilution, and the supernatant was obtained after shaking completely. Fifty microliters of each extracted sample was diluted with 150 μL of 15% methanol before detection with LC-MS/MS. For unbound vancomycin, 10 μL of each thawed ultrafiltrate sample was appropriately diluted with 70 μL of blank ultrafiltrate (including 0.1 mg/L IS). The latter was achieved using a ChromCore™ 120 C_{18} column (3 μm, 100 mm×2.1 mm; NanoChrom Technologies [Suzhou]). The upper and lower limits of quantification were 0.3125 mg/L and 20 mg/L, respectively. The inter- and intraday coefficients of variation as determined by high (10 mg/L), medium (1.25 mg/L) and low (0.67 mg/L) quality control samples were less than 12.6%.

Mass spectrometry analysis was performed on an API4000™ triple-quadrupole mass spectrometer equipped with a TurboIonSpray ionization source (AB Sciex Instruments, USA). Quantifications were performed in positive ionization mode with multiple reaction monitoring for the following transitions: m/z 725.6→144.3 for vancomycin and m/z 343.2→239.2 for IS. The detection parameters were optimized as follows: turbo gas temperature, 550°C; ion spray voltage, 5500 V; declustering potential, 42 for vancomycin and 100 for IS; and collision energy, 20 for vancomycin and 55 for IS. Gradient elution was applied with methanol (supplemented with 0.1% formic acid, mobile phase A) and 0.1% formic acid (v/v, mobile phase B) at a flow rate of 0.4 mL/min. The following gradient program was used for plasma separation: 0–0.3 min, 12% A; 0.3–0.8 min, 12–85% A; 0.8–2.2 min, 85% A. The column temperature was maintained at 40°C, and the injection volume was 5 μL.

The level of vancomycin was calculated by integration of the peak area ratio between vancomycin and triazolam based on standard calibration curves. The unbound vancomycin fraction (percent) was calculated according to the following equation: (ultrafiltrate level/total vancomycin level) × 100.\(^{11,19}\)

**Model Validation**

The performance of the prediction model was assessed for model validation of the unbound vancomycin estimate. The study cohort for validation of the prediction tool consisted of an additional 13 hospitalized adult patients in the ICU ward and 6 hospitalized adult patients in the non-ICU ward with clinically indicated vancomycin samples (based on archived samples). The methodology used for modeling, including sample collection, data collection and unbound vancomycin measurement, was also used for model validation. Goodness of fit was assessed by regression with an observed-versus-predicted plot and Bland–Altman analysis, and model validation was performed based on bias and precision.\(^{14}\) Mean bias was calculated according to the following equation as previously reported:\(^{14}\) \(\text{Mean bias} = \frac{1}{n}\sum (\text{predicted unbound vancomycin level} - \text{observed unbound vancomycin level})\), where n is the number of predicted unbound vancomycin levels. Mean precision was calculated according to the following equation as previously reported:\(^{14}\) \(\text{Mean precision} = \frac{1}{n}\sum |(\text{predicted unbound vancomycin level} - \text{observed unbound vancomycin level})|/\text{predicted unbound vancomycin level}\), where n is the number of predicted unbound vancomycin levels.

**Statistical Analysis**

Statistical analysis was performed with SPSS statistical software (version 19.0; SPSS Inc., Chicago, Illinois, USA). Bland–Altman analysis and Spearman correlation analysis were performed with MedCalc statistical software (version 20; MedCalc, Ostend, Belgium). Collected data are expressed as the mean ± SD for continuous variables with a Gaussian distribution, while the median (min, max) was used for continuous variables without Gaussian distribution. Categorical variables are presented as
frequencies and percentages. Differences between different patient wards were assessed with the Mann–Whitney U-test.

Correlations between total and unbound vancomycin levels were investigated by using scatterplots combined with Spearman correlation analysis. To identify potential predictors from variables extracted from patient characteristics for the unbound vancomycin level, we used linear regression analyses. Patient baseline data, such as history of diabetes mellitus, heart failure, dialysis and hepatic dysfunction, were defined as patients with a history of diabetes mellitus = 1 and patients with no history of diabetes mellitus = 0. All tests were two-sided, and a P value of <0.05 was considered statistically significant.

Results
Patient Characteristics
A total of 190 samples from 152 patients (95 patients in the ICU ward and 57 patients in the non-ICU ward) aged 18 years and older who received vancomycin for suspected or proven gram-positive infections and required routine total vancomycin TDM were included. The mean age at the time of vancomycin treatment was 56.03 ± 16.68 years (median: 58 years; range: 18–90 years). When separated by ward, 95 patients were from the ICU ward, and 57 were from the non-ICU ward. In the ICU ward, there were 13 patients with a history of diabetes mellitus, 11 patients with a history of heart failure and 5 patients with a history of hepatic dysfunction. In the non-ICU ward, there were 14 patients with a history of diabetes mellitus, 13 patients with a history of heart failure, 12 patients with a history of dialysis and 5 patients with a history of hepatic dysfunction. The remaining demographic and patient characteristics collected are summarized in Table 1. The distributions of total bilirubin levels in the different patient populations are shown with box-and-whisker plots in Figure 1.

The Unbound Vancomycin Fractions and the Correlation Between Free Vancomycin Level and Total Vancomycin Level
The mean total vancomycin level was 16.57 ± 14.13 mg/L (median: 12.44 mg/L; range: 1.79–104.50 mg/L) among the samples from the total study population, 15.73 ± 13.80 mg/L (median: 12.55 mg/L; range: 1.79–104.50 mg/L) among the ICU ward samples and 17.90 ± 14.65 mg/L (median: 12.41 mg/L; range: 3.21–71.0 mg/L) among the non-ICU ward samples. The mean unbound vancomycin level was 7.78 ± 7.44 mg/L (median: 5.54 mg/L; range: 0.11–49.44 mg/L) among the total population samples, 7.10 ± 6.31 mg/L (median: 5.70 mg/L; range: 0.11–33.40 mg/L) among the ICU ward samples and 8.89 ± 8.90 mg/L (median: 5.12 mg/L; range: 0.50–49.44 mg/L) among the non-ICU ward samples. The mean unbound vancomycin fraction was 45.80% ± 18.69% (median, 46.01%; range: 2.13–99.45%) among the total population samples, 44.47% ± 17.15% (median, 45.19%; range: 2.13–92.07%) among the ICU ward samples and 47.94% ± 20.88% (median, 49.01%; range: 7.60–99.45%) among the non-ICU ward samples. As shown in Figure 2, no significant differences in the total vancomycin level (Figure 2A, P=0.475), unbound vancomycin level (Figure 2B, P=0.440) or unbound vancomycin fraction (Figure 2C, P=0.359) were found between the populations in the ICU ward and the non-ICU ward (Mann–Whitney U-test).

The correlation between the unbound vancomycin level and total vancomycin level among patients in the different wards is described in Figure 3. Among the total population samples, the unbound vancomycin level was strongly correlated with the total vancomycin level (Figure 3A; R=0.860, P<0.01). A significant correlation could also be established between unbound vancomycin level and total vancomycin level for the patients in the ICU ward (Figure 3B; R=0.871, P<0.01) and in the non-ICU ward (Figure 3C; R=0.866, P<0.01), respectively.

Regression Analysis
The variables included in the multiple linear mixed model were age, BMI, creatinine level, cystatin C level, prealbumin level, total protein level, globulin level, albumin level, total bilirubin level, direct bilirubin level, number of concomitantly administered drugs with >70% PPB, history of diabetes mellitus, heart failure, dialysis, hepatic dysfunction and total vancomycin level. As shown in Table 2, the multiple linear mixed model analysis indicated that the total vancomycin level was the strongest predictor of the unbound vancomycin level among patients in the ICU ward, patients in the non-ICU ward and all patients (β=0.864, SE=0.023, P=0.000; β=0.866, SE=0.048, P=0.000; and β=0.863, SE=0.023, P=0.000, respectively). Other variables found to be predictive of the unbound vancomycin level were BMI (β=−0.102, SE=0.084, P=0.021) among all patients and total bilirubin (β=0.110, SE=0.009, P=0.035) among the ICU ward patients. The results indicated that the unbound vancomycin level can...
be predicted with the following equation: unbound vancomycin level = 0.395 × total vancomycin level + 0.019 × total bilirubin level + 0.468 (R² = 0.771) for patients in the ICU ward, where the total vancomycin level is in milligrams per liter and the total bilirubin level is in micromoles per liter. The unbound vancomycin level can be predicted with the following equation: unbound vancomycin level = 0.526 × total vancomycin level - 0.527 (R² = 0.749) for patients in the non-ICU ward, where the total vancomycin level is in milligrams per liter and the BMI is expressed in kilograms per square meter.

Model Validation
Validation of our prediction model for patients in the ICU ward was evaluated by using data from 13 patients aged 18 years or older in the ICU ward. The total vancomycin level was 15.50 ± 7.20 mg/L (median: 17.56 mg/L; range: 3.77–26.84 mg/L). The total bilirubin level was 26.31 ± 46.59 mg/L (median: 15.85 mg/L; range: 3.47–209.80 mg/L). The observed-versus-predicted plots and Bland–Altman analysis for the patients included in the validation model.

Table 1 Patient Demographic and Baseline Characteristics on the Day of Sampling of Patients Treated with Vancomycin

| Parameter                        | ICU        | Non-ICU    | ALL       |
|----------------------------------|------------|------------|-----------|
| No. patients                     | 95         | 57         | 152       |
| No. samples                      | 117        | 73         | 190       |
| No. patients with diabetes mellitus | 13       | 14         | 27        |
| No. patients with heart failure  | 11         | 13         | 24        |
| No. patients with dialysis       | 0          | 12         | 12        |
| No. patients with hepatic dysfunction | 5          | 5          | 10        |
| Age (year)                       | 64 (18–88) | 49 (18–90) | 57 (18–90) |
| Male/female ratio                | 62/33      | 39/18      | 101/51    |
| BMI (kg/m²)                      | 24.22 (16.44–36.05) | 23.81 (17.90–40.75) | 24.21 (16.44–40.75) |
| Creatinine level (µmol/L)        | 68.10 (18.93–740.20) | 83.40 (36.3–1104.9) | 74.0 (18.93–1104.9) |
| Cystatin C level (mg/L)          | 1.12 (0.51–7.38) | 1.21 (0.57–10.40) | 1.14 (0.51–10.40) |
| Prealbumin level (g/L)           | 167.6 (48.0–383.8) | 210.0 (42.0–418.5) | 173.25 (42.0–418.5) |
| Total protein level (g/L)        | 57.82 (39.04–99.90) | 59.34 (40.30–99.90) | 59.02 (39.04–99.90) |
| Globulin level (g/L)             | 26.51 (13.15–40.10) | 27.30 (14.50–62.10) | 27.16 (13.15–62.10) |
| Albumin level (g/L)              | 32.31 (20.68–64.50) | 35.10 (21.20–60.0) | 33.8 (20.68–64.50) |
| Total bilirubin level (µmol/L)   | 10.91 (3.30–258.06) | 9.22 (2.50–68.90) | 10.0 (2.50–258.06) |
| Direct bilirubin level (µmol/L)  | 4.49 (0.74–228.26) | 3.30 (0.11–38.57) | 4.26 (0.11–228.26) |

| Type of infection                | ICU        | Non-ICU    | ALL       |
|----------------------------------|------------|------------|-----------|
| Osteomyelitis                    | 8 (6.8%)   | 5 (6.8%)   | 13 (6.8%) |
| Septicemia                       | 33 (28.2%) | 12 (16.4%) | 45 (23.7%)|
| Intracranial infection           | 21 (17.9%) | 12 (16.4%) | 33 (17.4%)|
| Infective endocarditis           | 7 (6.0%)   | 14 (19.2%) | 21 (11.1%)|
| Skin and soft tissue             | 21 (17.9%) | 9 (12.3%)  | 30 (15.8%)|
| Other                            | 27 (23.1%) | 21 (28.8%) | 48 (25.3%)|

| No. coadministered drugs with >70% PPB | ICU        | Non-ICU    | ALL       |
|----------------------------------------|------------|------------|-----------|
|                                        | 0 (0–2)    | 0 (0–2)    | 0 (0–2)   |

Note: Descriptive data are presented as the median (min, max) or no. (%) of patients.

Abbreviations: ICU, intensive care unit; BMI, body mass index; PPB, plasma protein binding.
In this study, we validated unbound vancomycin fraction in a relatively large cohort of different patient populations, including 117 samples from 95 ICU patients and 73 samples from 57 non-ICU patients. Previous studies have already found a large variation in the unbound vancomycin fraction, ranging from nearly 0% to almost 100%.\textsuperscript{15-21} Our present study showed that the unbound vancomycin fraction ranged from 2.13% to 99.45% in the overall patient population, which is consistent with the abovementioned previous studies.

Because PPB changes of drugs are common among ICU patients,\textsuperscript{26,27} we compared the unbound vancomycin fraction between ICU patients and non-ICU patients but found no significant differences (P=0.359). Consistent with our findings, some studies also examined the effect of ICU location on the unbound vancomycin fraction and found no significant differences.\textsuperscript{18,19} Another previous study showed that ICU patients had a protein binding value that was 8.4% lower than that of non-ICU patients.\textsuperscript{3} Notably, however, only 55 patients were included in that study, including 14 ICU patients.

Whether the unbound vancomycin level can be predicted from the total vancomycin level remains controversial. We performed a study with a relatively large cohort to evaluate the extent to which unbound and total vancomycin levels are correlated. We found that a significant correlation could be established between the unbound vancomycin level and the total vancomycin level among all patients (R=0.860, P<0.01), among ICU patients (R=0.871, P<0.01) and among non-ICU patients (R=0.866, P<0.01), which more or less agrees with the viewpoints of previous studies.\textsuperscript{11,14,19-21} Contrasting results concluded that the unbound vancomycin level is independent of the total vancomycin level.\textsuperscript{18} Of note, the study did not include a large patient population, with 65 samples from 15 patients, and the patients received vancomycin by continuous infusion, whereas our patients received vancomycin by intermittent infusion, potentially explaining this contradiction.

Linear regression was selected to model the data because stepwise regression could be used to attempt to relate the unbound vancomycin level to one or more of the available clinical patient data points and establish a parsimonious equation for predicting the unbound vancomycin level. We found that total bilirubin was a predictor of unbound vancomycin levels in ICU ward patients, a novel finding that has not been reported in previous models to our knowledge. As described in Figure 1, the level of total bilirubin ranges widely among ICU patients and may function as a predictor of unbound vancomycin level because it can expel vancomycin from albumin and bind to it.\textsuperscript{28} Elevating unbound vancomycin levels. Our results therefore indicate that total bilirubin

\begin{figure}[h]
\centering
\includegraphics[width=0.8\textwidth]{figure1}
\caption{The distributions of total bilirubin level in the different patient populations are shown with box-and-whisker plots. The data are presented as boxes indicating the 2.5th, 25th, 50th (median), 75th, and 97.5th percentiles. Statistically nonsignificant difference (P>0.05, Mann–Whitney U-test) is not shown between patients in the ICU ward and non-ICU ward.}
\end{figure}
The distributions of total vancomycin level (A), unbound vancomycin level (B) and unbound vancomycin fractions (C) in the different patient populations are shown with box-and-whisker plots. The data are presented as boxes indicating the 2.5th, 25th, 50th (median), 75th, and 97.5th percentiles. Statistically nonsignificant differences (P>0.05, Mann–Whitney U-test) are not shown between patients in the ICU ward and non-ICU ward.

Figure 2
Figure 3 The correlation between the unbound vancomycin level and total vancomycin level among the total (A), ICU ward (B) and non-ICU ward (C) patient populations.
could be a potential predictor of unbound vancomycin level in the clinic. Similar to previous observations, 18,25 significant correlations between the unbound vancomycin level and total protein level and albumin in our study population could not be demonstrated. This is puzzling since the PPB characteristics of vancomycin were also believed to be correlated predominantly with albumin, 15,19,29 total protein 14 and IgA 11,15,19,30 levels in previous studies. Although we included a relatively large study population, we were still unable to correlate the unbound vancomycin level and the albumin level. In future studies, we will include a larger population, which may finally uncover a correlation between these two compounds. Regarding the impact of the IgA level, as the study was retrospective and noninterventional, the IgA level was not measured in our study population, thus excluding comparisons with previous studies.

Compared with previous studies, we included a larger study population and more comprehensive potential covariates, such as coadministration of drugs with PPB>70% and baseline data, including not only routine biochemical data but also history of diabetes mellitus, heart failure, dialysis and hepatic dysfunction. A linear regression model was applied to attempt to relate the unbound vancomycin level to one or more of these additional parameters but without success. Coadministration of drug combinations with PPB>70%, including vitamin K antagonists, aspirin and NSAIDs, on the day of sampling in our study was known, especially to expel vancomycin from albumin. 19,31 Although these drugs are expected to be able to expel vancomycin from albumin and elevate unbound vancomycin levels, no significant correlation between the unbound vancomycin level and the number of coadministered drugs with a PPB>70% was found in either our study or a previous study. 19 Among patients on dialysis, Tan et al 32 studied 6 patients with renal failure and concluded that this population had a higher unbound vancomycin fraction and that the mechanism may be attributed to a reduced albumin binding affinity and competition with accumulated endogenous substrates due to reduced renal clearance. 33 The opposite result was observed by Butterfield et al 14 who found

Table 2 Variables Used in Constructing a Model Estimating Unbound Vancomycin Level by Multivariable Linear Regression

| Variable            | β     | SE   | P value |
|---------------------|-------|------|---------|
| Total patients      |       |      |         |
| Total vancomycin level (mg/L) | 0.863 | 0.023 | 0.000   |
| BMI (kg/m²)         | -0.102| 0.084| 0.021   |
| ICU patients        |       |      |         |
| Total vancomycin level (mg/L) | 0.864 | 0.023 | 0.000   |
| Total bilirubin (µmol/L) | 0.110 | 0.009 | 0.035   |
| Non-ICU patients    |       |      |         |
| Total vancomycin level (mg/L) | 0.866 | 0.048 | 0.000   |

Abbreviations: BMI, body mass index; ICU, intensive care unit; β, β coefficient; SE, standard error.

Figure 4 Validation of the prediction model for patients in the ICU ward. (A) Correlation between the observed unbound vancomycin level and predicted unbound vancomycin level. (B) Bland–Altman analysis of the observed unbound vancomycin level plotted against the predicted unbound vancomycin level. Horizontal dashed lines are drawn at the mean difference (milligrams per liter) and at the limits of agreement (LOAs).
a reduced unbound vancomycin level in patients on dialysis. Our study concluded that dialysis had no effect on unbound vancomycin levels, which is not congruent with the above studies. The different conclusions may be explained by the fact that various proteins affect protein binding, and it is possible that proteins unaffected by reduced renal clearance played a role in the unbound vancomycin level in our study population. It should also be pointed out that vancomycin (with a molecular weight of 1450 Da) is not considered “dialyzable” with older (pre-1990s) hemodialyzers. As hemodialysis technology has produced far more permeable membranes, vancomycin is currently thought to be cleared substantially by contemporary high-permeability hemodialyzers. Moreover, different methods of administration, such as the intravenous administration of vancomycin after the dialysis treatment used in our study population or administration of vancomycin during the last hour of dialysis treatment, may also influence unbound vancomycin levels or fraction. These reasons may explain the different conclusions. To further shed light on this disputed conclusion, an additional investigation in a larger dialysis population should be performed to evaluate whether dialysis can influence the unbound vancomycin fraction and which accumulated endogenous substrates are able to expel vancomycin from proteins.

Several notable limitations also exist and should be mentioned. First, this study employed a retrospective and noninterventional design with a limited sample size (eg, only 12 patients on dialysis were in the non-ICU ward group in this study) and the possibility of including other unknown factors. Second, the findings are limited to our center because this study was based on patients at a single center rather than at multiple centers. Future studies should include a larger study population at multiple centers, which may provide a more reliable model for clinicians to estimate the unbound vancomycin level. Third, due to a deficiency of the IgA test obtained on the day of vancomycin sample collection for routine total vancomycin measurement, we were not able to assess the correlation between the unbound vancomycin level and the IgA level, which has been analyzed in many other studies. However, despite these limitations, this study still provides a reference for clinicians to improve the understanding of the predictors of the unbound vancomycin level. Our study refines the current understanding of the factors that modify the unbound vancomycin level and improves the clinician’s ability to predict the unbound vancomycin level in an adult patient.

### Conclusions

As we observed a significant correlation between total and unbound vancomycin levels in the ICU patient population and non-ICU patient population, measurement of the unbound vancomycin level seems to have no added value over measurement of the total vancomycin level. In addition, we also found that total bilirubin was a predictor of the unbound vancomycin level in ICU ward patients. Furthermore, the favorable predictive performance of the
prospective model validation suggests the final parsimonious mathematical equations that can be used as a practical alternative to predict the unbound vancomycin level in a given adult being treated with vancomycin.

**Abbreviations**
ICU, intensive care unit; AUC, area under the curve; MIC, minimum inhibitory concentration; BMI, body mass index; LC-MS/MS, liquid chromatography-tandem mass spectrometry; TDM, therapeutic drug monitoring; PPB, plasma protein binding; NSAIDs, nonsteroidal anti-inflammatory drugs; IS, internal standard.

**Data Sharing Statement**
All data generated or analyzed during this study are included in the article.

**Ethical Considerations and Publications**
This study was approved by the Institute Medical Ethics Committee of the Affiliated Hospital of Qingdao University on 3 January 2018. This study was conducted in accordance with the Declaration of Helsinki. As the study was performed with archived samples, the requirement for informed consent was waived by the Institute Medical Ethics Committee, but patient confidentiality was protected. Written informed consent for publication was obtained from all coauthors participated to the research.

**Acknowledgment**
This work was supported by the Natural Science Foundation of Shandong Province (grant No. ZR2019BH026).

**Author Contributions**
All authors made significant contributions to the research reported, whether in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the research work.

**Disclosure**
The authors report no competing interests in this work.

**References**

1. Oliveira MS, Machado AS, Mendes ET, et al. Pharmacokinetic and pharmacodynamic characteristics of vancomycin and meropenem in critically ill patients receiving sustained low-efficiency dialysis. *Clin Ther.* 2020;42(4):625–633. doi:10.1016/j.clinthera.2020.02.011

2. Qin X, Tsai MF, Zhao X, Zhang L, Qi Z, Cheung BMY. Vancomycin-associated acute kidney injury in Hong Kong in 2012–2016. *BMC Nephrol.* 2020;21(1):41. doi:10.1186/s12882-020-1704-4

3. Crandon JL, MacVane SH, Nicolau DP. Clinical laboratory-based assay methodologies may underestimate and increase variability of vancomycin protein binding in hospitalized patients. *Pharmacotherapy.* 2014;34(2):203–209. doi:10.1002/phar.1323

4. Rybak MJ, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm.* 2009;66(1):82–98. doi:10.2146/ajhp080434

5. Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm.* 2020;77(11):835–864. doi:10.1093/ajhp/zxaa036

6. Rybak MJ, Le J, Lodise T, et al. Executive summary: therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: a revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *J Pediatr Infect Dis Soc.* 2020;9(3):281–284. doi:10.1093/jpids/piaa057

7. Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. Generic vancomycin products fail in vivo despite being pharmaceutically equivalent of the innovator. *Antimicrob Agents Chemother.* 2010;54(8):3271–3279. doi:10.1128/AAC.01044-09

8. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. *Clin Infect Dis.* 2006;42(Suppl 1):S35–39. doi:10.1086/491712

9. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. *Nat Rev Microbiol.* 2004;2(4):289–300. doi:10.1038/nrmicro8682

10. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. *Arch Intern Med.* 2006;166(19):2138–2144. doi:10.1001/archinte.166.19.2138

11. Stove V, Coene L, Carlier M, De Waele JJ, Fiers T, Verstraete AG. Measuring unbound versus total vancomycin concentrations in serum and plasma: methodological issues and relevance. *Ther Drug Monit.* 2015;37(2):180–187. doi:10.1097/FTD.0000000000000122

12. Ackerman BH, Taylor EH, Olsen KM, Abdel-Malak W, Pappas AA. Vancomycin serum protein binding determination by ultrafiltration. *Drug Intell Clin Pharm.* 1988;22(4):300–303. doi:10.1177/10600288022200404

13. Albrecht LM, Rybak MJ, Warbasse LH, Edwards DJ. Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. *DICP Ann Pharmacother.* 1991;25(7–8):713–715. doi:10.1177/106002809102500701

14. Butterfield JM, Patel N, Pai MP, Rosano TG, Drusano GL, Lodise TP. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. *Antimicrob Agents Chemother.* 2011;55(9):4277–4282. doi:10.1128/AAC.01674-10

15. Sun H, Maderazo EG, Kruessel AR. Serum protein-binding characteristics of vancomycin. *Antimicrob Agents Chemother.* 1993;37(5):1132–1136. doi:10.1128/AAC.37.5.1132
16. Chen Y, Norris RL, Schneider JJ, Ravenscroft PJ. The influence of vancomycin concentration and the pH of plasma on vancomycin protein binding. J Pharmacol Toxicol Methods. 1992;28(1):57–60. doi:10.1016/1056-8719(92)90066-A

17. Dykhuisen RS, Harvey G, Stephenson N, Nathwani D, Gould IM. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother. 1995;39(8):1842–1847. doi:10.1128/AAC.39.8.1842

18. Berthoin K, Ampe E, Tulkens PM, Carryn S. Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections. Int J Antimicrob Agents. 2009;34(6):555–560. doi:10.1016/j.ijantimicag.2009.08.005

19. Oyaert M, Spriet I, Allegaert K, et al. Factors impacting unbound vancomycin concentrations in different patient populations. Antimicrob Agents Chemother. 2015;59(11):7073–7079. doi:10.1128/AAC.01185-15

20. De Cock PA, Desmet S, De Jaeger A, et al. Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board? J Antimicrob Chemother. 2017;72(3):801–804. doi:10.1093/jac/dkw495

21. Smits A, Pauwels S, Oyaert M, et al. Factors impacting unbound vancomycin concentrations in neonates and young infants. Eur J Clin Microbiol Infect Dis. 2018;37(8):1503–1510. doi:10.1007/s10096-018-3277-8

22. Uldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50(2):99–110. doi:10.2165/11539220-000000000-00000

23. Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother. 2012;67(6):1305–1310. doi:10.1093/jac/dks066

24. Rice TL. Simplified dosing and monitoring of vancomycin for the burn care clinician. Burns. 1992;18(5):355–361. doi:10.1016/0305-4179(92)90032-P

25. Kees MG, Wicha SG, Seefeld A, Kees F, Kloft C. Unbound fraction of vancomycin in intensive care unit patients. J Clin Pharmacol. 2014;54(3):318–323. doi:10.1002/jcph.175

26. Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013;52(1):1–8. doi:10.1007/s40262-012-0018-5

27. Kratzer A, Liebchen U, Schleibinger M, Kees MG, Kees F. Determination of free vancomycin, ceftriaxone, cefazolin and etrapenem in plasma by ultrafiltration: impact of experimental conditions. J Chromatogr. 2014;961:97–102. doi:10.1016/j.jchromb.2014.05.021

28. Wang Y, Sheng G, Shi L, Cheng X. Increased serum total bilirubin-albumin ratio was associated with bilirubin encephalopathy in neonates. Biosci Rep. 2020;40(1).

29. Wu J, Wei R, Wang H, Li T, Ren W. Underlying the mechanism of vancomycin and human serum albumin interaction: a biophysical study. J Biochem Mol Toxicol. 2013;27(10):463–470. doi:10.1002/jbt.21511

30. Cantu TG, Dick JD, Elliott DE, Humphrey RL, Kornhauser DM. Protein binding of vancomycin in a patient with immunoglobulin A myeloma. Antimicrob Agents Chemother. 1990;34(7):1459–1461. doi:10.1128/AAC.34.7.1459

31. Vanstraalen K, Wauters J, Vercammen I, et al. Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients. Antimicrob Agents Chemother. 2014;58(11):6782–6789. doi:10.1128/AAC.03641-14

32. Tan CC, Lee HS, Ti TY, Lee EJ. Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure. Ther Drug Monit. 1990;12(1):29–34. doi:10.1097/00007691-199001000-00006

33. Dreischbach AW, Lertora J. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4(8):1065–1074. doi:10.1517/17425255.4.8.1065

34. Quale JM, O’Halloran JN, DeVincenzo N, Barth RH. Removal of vancomycin by high-flux hemodialysis membranes. Antimicrob Agents Chemother. 1992;36(7):1424–1426. doi:10.1128/AAC.36.7.1424

35. Nyman HA, Agarwal A, Senekjian HO, Leypoldt JK, Cheung AK. Removal of vancomycin administered during dialysis by a high-flux dialyzer. Hemodialysis Int. 2018;22(3):383–387. doi:10.1111/hdi.12637